Abstract
The US RADx program has spawned a phalanx of diagnostic products to market in just 12 months. Its long-term impact on point-of-care, at-home and population testing may be even more profound.
MeSH terms
-
COVID-19 / diagnosis*
-
Direct-To-Consumer Screening and Testing / economics*
-
Drug Development / economics*
-
Early Diagnosis
-
Government Programs / economics
-
Government Programs / organization & administration
-
Humans
-
National Institutes of Health (U.S.)
-
Point-of-Care Systems / economics*
-
United States